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Previewsinteractions. Specifically, CASK is known
to interact with ZO1, which interacts with
JAM2, which interacts with Pard3, thus
bringing CASK and Pard3 into proximity.
However, the work presented here shows
that CASK and Pard3 interact directly
through dimerization of their PDZ do-
mains. Why these two proteins interact
directly requires further investigation, but
now that Chang et al. (2011) have identi-
fied every PDZ-PDZ interaction from the
mouse proteome, they have paved the1072 Chemistry & Biology 18, September 23,way for establishing the biological signifi-
cance of these interactions.REFERENCES
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Casein lytic peptidase P (ClpP) is a serine peptidase that, when coupled to its cognate ATPase, facilitates the
controlled degradation of both damaged and unwanted proteins in bacteria. In this issue of Chemistry &
Biology, Leung et al. (2011) report a small molecule screen against ClpP, fromwhich they identified four struc-
turally distinct compounds that activate ClpP for unregulated proteolysis.The treatment of bacterial infections with
antimicrobial drugs was one of the most
profound medical advances of the last
century. The discovery of these drugs
began in the 1930s and continued
unabated over the next four decades.
Indeed, many of the drugs we use today
can be traced back to natural compounds,
identified during these ‘‘golden’’ years of
drug discovery, and their effectiveness is
evidenced by our current quality of life.
However,since theendof this fruitful period
of drug discovery, relatively few new
compounds (natural or synthetic) have
beendeveloped.Concomitantly,especially
during the last decade, there has been a
concerning increase in the occurrence of
nosocomial infections involving drug resis-
tant bacterial species (e.g., Methicillin-
resistant Staphylococcus aureus [MRSA]
and Vancomycin-resistant Enterococi
[VRE]) (Levy and Marshall, 2004) that has
in turn lead to the emergence of multi-
drug resistant (MDR)bacteria.Hence, there
is a real need for the development of new
drugs, especially those that target novel
mechanisms to kill bacterial cells.In 2005, Bro¨tz-Oesterhelt and col-
leagues identified a new class of natural
antibiotics termed acyldepsipeptides
(ADEPs) that showed remarkable pro-
mise, as they were active in the treatment
of rodents infectedwith antibiotic resistant
bacteria (Bro¨tz-Oesterhelt et al., 2005).
Surprisingly, these compounds do not kill
bacteria by inhibiting an essential cellular
process, but rather they target a non
essential protein, the peptidase ClpP, to
kill bacteria. Indeed ADEPs are proposed
to kill bacteria via a unique mechanism—
by triggering the widespread and unregu-
lateddegradationof nascentpolypeptides
and unfolded proteins (Kirstein et al.,
2009). Despite their remarkable bacteri-
cidal activity, limited availability of these
antibiotics has hampered progress in
elucidating their mechanism of action;
hence the identification of new ClpP acti-
vators of unregulated proteolysis may aid
in further defininghow this promising class
of drug functions.
ClpP is a barrel-shaped protein com-
posed of two heptameric rings in which
the catalytic residues are sequesteredinside a proteolytic chamber. In the
absence of its cognate AAA+ (ATPase
associated with various cellular activities)
component (e.g., ClpA, ClpC or ClpX),
entry into this chamber is restricted to
a narrow entry portal at either end of the
complex (Wang et al., 1997). In this state,
although short peptides can enter the
proteolytic chamber for hydrolysis, large
polypeptides are generally excluded
from the chamber, preventing the indis-
criminate degradation of cellular proteins.
Therefore, in the absence of its cognate
ATPase, protein degradation by ClpP is
effectively turned OFF (Figure 1). By con-
trast, in the presence of its cognate
ATPase, ClpP-mediated protein degrada-
tion is turned ON (Figure 1). Currently, it is
widely accepted that activation of ClpP
results from docking of a specific loop
(known as the IGF loop) on the cognate
ATPase (Kim et al., 2001), which culmi-
nates in opening of the narrow entry portal
located at the distal ends of the complex,
supporting entry of unfolded polypep-
tides, into the proteolytic chamber (Bur-
ton et al., 2001).
Figure 1. Activators of Self-Compartmentalizing Proteases Turn ClpP On for ‘‘Unregulated’’ Proteolysis
ClpP-mediated protein degradation is normally a highly regulated process in bacteria. Under normal conditions, the degradation of large protein substrates by
single- or double-ringed oligomers of ClpP is effectively turned OFF (red) and only small peptides can access the catalytic residues located inside the proteolytic
chamber. Consistently, the pore of ClpP is ‘‘closed,’’ diameter of10 A˚ (red ring, left side). However, in the presence of its cognate ATPase (blue), ClpP is turned
ON (green) and the regulated degradation of selected substrates (e.g., SsrA-tagged proteins) can proceed. The SsrA tag is an 11 amino acidmotif, attached to the
C terminus of ‘‘stalled’’ translation products in bacteria, that is essential for ATPase-mediated recognition of these incomplete proteins. By contrast, ACPs and
ADEPs (yellow) activate ClpP for unregulated protein degradation by opening the pore to a diameter 20 A˚ (green ring, right side), permitting the entry of large
unfolded proteins into the catalytic chamber of ClpP in the absence of its cognate ATPase component.
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PreviewsIn the current study, Leung et al. (2011)
exploit the idea that ClpP is a useful drug
target and have developed a simple fluo-
rescence-based assay to identify small
molecules that activate ClpP for ATPase-
independent or ‘‘unregulated’’ degrada-
tion of large polypeptides. Specifically,
they employed a high-throughput screen
to monitor the ClpP-mediated degrada-
tion of a fluorescently labeled model
‘‘unfolded’’ protein (Fluorescein isothio-
cyanate labeled casein or FITC-casein).
In the absence of ClpP activation, FITC-
casein is stable, and hence the fluo-
rescence signal is quenched; however
upon activation of ClpP, FITC-casein isdegraded into short FITC-labeled pep-
tides, which are highly fluorescent. Using
this assay, the authors screened approxi-
mately 60,000 smallmolecules fromwhich
they identified five new compounds
(belonging to four different structural
classes), called activators of self-compart-
mentalizing proteases (ACPs; ACP1–
ACP5). Importantly, all five compounds
were able to trigger the nonspecific degra-
dation of several ‘‘unfolded’’ proteins;
however, some compounds were consid-
ered better ClpP activators than others,
as they were able to trigger the degrada-
tion of a broader range of substrates.
From these five compounds, the best acti-Chemistry & Biology 18, September 23, 2011 ªvator of ClpP - ACP1 (which was also
considered to display gooddrug-like char-
acteristics) was chosen for optimization
and over 70 new derivatives were created,
one of which (ACP1b) exhibited dramati-
cally improved binding characteristics
and activation qualities when compared
to the parent compound.
Usingavarietyofbiophysical techniques,
the authors revealed that ACPs, like their
natural cousins (ADEPs), activate ClpP
through stabilization of the tetradecamer
(Figure 1). Indeed, there was a good corre-
lation between the binding affinity of the
compound, stabilization of the double-
ringed oligomer and activation of ClpP.2011 Elsevier Ltd All rights reserved 1073
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PreviewsAlso, through a combination of molecular
docking simulations and biochemical ex-
periments using various ClpP mutant pro-
teins, the authors proposed that ACPs
target two pockets on the surface of ClpP.
StrongACPs (e.g., ACP1b) bind exclusively
to a hydrophobic pocket (H-pocket)
located on the apical surface of ClpP, while
weak ACPs (e.g., ACP2) appear to bind to
both the H-pocket and a second pocket
called the C-pocket (as it contains several
charged residues), which is formed by the
interface of two adjacent subunits in the
heptameric ring. Consistent with an impor-
tant role for theH-pocket inClpPactivation,
recent structural analysis of ClpP in
complex with ADEP (Lee et al., 2010; Li
et al., 2010) revealed that ADEPs dock
into theH-pocket,causingaconformational
change in ClpP that triggers a dramatic
opening of the entry portal into the proteo-
lytic chamber (see Figure 1, right side).
Interestingly, the ClpP activators (that
bind exclusively to the H-pocket) not only
trigger unregulated degradation of un-
folded proteins in the absence of the
cognate ATPase, but also inhibit the tightly
regulated degradation of a model SsrA-
tagged protein (i.e., GFP-ssrA), which
represents an ATPase-dependent sub-
strate. Collectively, these findings suggest
that chemical activators of ClpP, such as1074 Chemistry & Biology 18, September 23,ACPs and ADEPs, may function as IGF-
loop mimetics, and hence these com-
pounds may prove useful, not only in the
development of future antimicrobial drugs
but also in providing useful mechanistic
insights into how ATPase(s) activate ClpP
for degradation. Indeed this work rein-
forces the utility of ClpP as a potential
drug target and provides a number of new
structural frameworks from which poten-
tially useful ClpP activators could
be further developed into antibacterial
drugs. Nevertheless, given that ClpP is
also expressed in mammalian mitochon-
dria where it is proposed to play an impor-
tant role in the mitochondrial specific
unfolded protein response, one may need
tobecautiousabout theuseofantibacterial
drugs that target ClpP until the effect of
these drugs has been studied on human
ClpP and mitochondrial function. Alterna-
tively, drugs that target HslV (a bacterial
self-compartmentalized protease that is
absent in higher eukaryotes) for unregu-
lated degradationmay have great promise.
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